CAR-T cell therapy for relapsed T-cell leukemia or lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immunotherapy called anti-CD7 CAR-T cells for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to see if these specially engineered immune cells can find and destroy cancer cells that carry the CD7 protein.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 0 and 29 years old.
- Your leukemia or lymphoma must have returned at least twice, or returned after a stem cell transplant, or not responded to chemotherapy.
- At least 90% of your cancer cells must have the CD7 protein (a marker on the cell surface).
- You must have a stem cell donor identified and be eligible for a stem cell transplant after this treatment.
- Your organs (kidneys, liver, lungs, heart) must be working well enough based on blood tests and scans.
- You cannot have certain active infections, serious heart problems, or active graft-versus-host disease needing strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from your own immune cells, designed to target and kill cancer cells that have a protein called CD7. It might help people with T-cell leukemia or lymphoma that has returned or not responded to standard treatments.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a personalized therapy where your child's own immune cells are modified to find and destroy cancer cells that carry a specific marker called CD7. It is for children and young adults whose T-cell leukemia or lymphoma has come back or not responded to standard treatments.
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
Hear when a new T-Cell Acute Lymphoblastic Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.